Amicus Therapeutics (FRA:AM6) Total Liabilities : €564.4 Mil (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Total Liabilities?

Amicus Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was €564.4 Mil.

Amicus Therapeutics's quarterly Total Liabilities declined from Jun. 2024 (€573.16 Mil) to Sep. 2024 (€547.57 Mil) but then increased from Sep. 2024 (€547.57 Mil) to Dec. 2024 (€564.39 Mil).

Amicus Therapeutics's annual Total Liabilities declined from Dec. 2022 (€567.46 Mil) to Dec. 2023 (€566.44 Mil) and declined from Dec. 2023 (€566.44 Mil) to Dec. 2024 (€564.39 Mil).

Amicus Therapeutics Total Liabilities Historical Data

The historical data trend for Amicus Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Total Liabilities Chart

Amicus Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

493.32

529.03

567.46

566.44

564.39

Amicus Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															566.44	543.81	573.16	547.57	564.39

Amicus Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Amicus Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	142.01	+	(415.605	+	6.779
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	564.4

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	749.707	-	185.313
	=	564.4

Amicus Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	142.01	+	(415.605	+	6.779
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	564.4

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	749.707	-	185.313
	=	564.4

Amicus Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (FRA:AM6) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

FOLD:USA 0HF9:UK AM6:Germany

Address

47 Hulfish Street, Princeton, NJ, USA, 08542

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines